Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. (ELDN): 2 pipeline candidates · ~14 mo cash runway · 3 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
14.1 months
D/E 1.03 · 48% dilution
Lead: Phase 1/Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Eledon Pharmaceuticals, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$285.6M
Cash
$6.2M
Quarterly Burn
$22.6M
Runway
14.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
| Drug | Phase |
|---|---|
| at-1501 | Phase 1/Phase 2 |
| tegoprubart | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
119
Total value held
$111.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 6,586,268 | $20.3M |
| bvf inc/il | 6,293,282 | $19.4M |
| blackrock, inc. | 4,382,245 | $13.5M |
| zimmer partners, lp | 1,875,000 | $5.8M |
| geode capital management, llc | 1,791,783 | $5.5M |
| sphera funds management ltd. | 1,772,131 | $5.5M |
| state street corp | 1,154,671 | $3.6M |
| awm investment company, inc. | 1,100,000 | $3.4M |
| jefferies financial group inc. | 1,094,456 | $3.4M |
| kingdon capital management, l.l.c. | 1,039,275 | $3.2M |
Showing top 10 of 119 institutional holders of Eledon Pharmaceuticals, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Eledon Pharmaceuticals, Inc.'s pipeline?
Eledon Pharmaceuticals, Inc. (ELDN) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Eledon Pharmaceuticals, Inc.'s lead drug candidate?
Eledon Pharmaceuticals, Inc.'s most advanced tracked candidate is at-1501 (Phase 1/Phase 2) for Kidney Transplant Rejection; Prevention of Rejection in Kidney Transplant.
What is Eledon Pharmaceuticals, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Eledon Pharmaceuticals, Inc. has approximately 14.1 months of cash runway.
What is Eledon Pharmaceuticals, Inc.'s market capitalization?
Eledon Pharmaceuticals, Inc.'s market capitalization is approximately $285.6M.
Who is the CEO of Eledon Pharmaceuticals, Inc.?
Dr. David-Alexandre C. Gros M.D., Ph.D. is the chief executive officer of Eledon Pharmaceuticals, Inc. (ELDN).
Get the full picture on Eledon Pharmaceuticals, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.